HALOPERIDOL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H23ClFNO2
Molecular Weight	375.8649
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C(CC(=O)c1ccc(cc1)F)CN2CCC(CC2)(c3ccc(cc3)Cl)O

InChI

InChIKey=LNEPOXFFQSENCJ-UHFFFAOYSA-N

InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB00502
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/015923s079lbl.pdf

Haloperidol is a phenyl-piperidinyl-butyrophenone that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorders, ballism, and Tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of Huntington disease. It is a potent antiemetic and is used in the treatment of intractable hiccups. Haloperidol also exerts sedative and antiemetic activity. Haloperidol principal pharmacological effects are similar to those of piperazine-derivative phenothiazines. The drug has action at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Haloperidol has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. The precise mechanism whereby the therapeutic effects of haloperidol are produced is not known, but the drug appears to depress the CNS at the subcortical level of the brain, midbrain, and brain stem reticular formation. Haloperidol seems to inhibit the ascending reticular activating system of the brain stem (possibly through the caudate nucleus), thereby interrupting the impulse between the diencephalon and the cortex. The drug may antagonize the actions of glutamic acid within the extrapyramidal system, and inhibitions of catecholamine receptors may also contribute to haloperidol's mechanism of action. Haloperidol may also inhibit the reuptake of various neurotransmitters in the midbrain, and appears to have a strong central antidopaminergic and weak central anticholinergic activity. The drug produces catalepsy and inhibits spontaneous motor activity and conditioned avoidance behaviours in animals. The exact mechanism of antiemetic action of haloperidol has also not been fully determined, but the drug has been shown to directly affect the chemoreceptor trigger zone (CTZ) through the blocking of dopamine receptors in the CTZ. Haloperidol is marketed under the trade name Haldol among others.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D4 receptor 20 Target ID: CHEMBL219 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14611858	Inverse Agonist 34	17.0 nM [EC50]
Dopamine D2 receptor 145 Target ID: CHEMBL217 Sources: http://www.drugbank.ca/drugs/DB00502	Antagonist 1131
Serotonin 2a (5-HT2a) receptor 100 Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7520908	Antagonist 1131	53.0 nM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Schizophrenia 131 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/015923s079lbl.pdf	Primary		Approved 4033	HALDOL Approved Use HALDOL (haloperidol) is indicated for use in the treatment of schizophrenia. HALDOL is indicated for the control of tics and vocal utterances of Tourette’s Disorder. Launch Date 5.059584E11
Tourette's syndrome 10 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/015923s079lbl.pdf	Primary		Approved 4033	HALDOL Approved Use HALDOL (haloperidol) is indicated for use in the treatment of schizophrenia. HALDOL is indicated for the control of tics and vocal utterances of Tourette’s Disorder. Launch Date 5.059584E11

Doses

Dose	Population	Adverse events
0.9 mg single, oral Overdose Dose: 0.9 mg Route: oral Route: single Dose: 0.9 mg Sources: https://pubmed.ncbi.nlm.nih.gov/28128816	unknown, 11 years n = 1 Health Status: unknown Age Group: 11 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/28128816	Other AEs: Drowsiness... Other AEs: Drowsiness (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/28128816
2 mg 4 times / day multiple, intramuscular Recommended Dose: 2 mg, 4 times / day Route: intramuscular Route: multiple Dose: 2 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: dementia-related psychosis Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf
5 mg 3 times / day multiple, oral Recommended Dose: 5 mg, 3 times / day Route: oral Route: multiple Dose: 5 mg, 3 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c559b0b0-4087-d12a-e718-c18ccb6811e6	unhealthy, adult Health Status: unhealthy Condition: dementia-related psychosis Age Group: adult Sources: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c559b0b0-4087-d12a-e718-c18ccb6811e6	Sources: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c559b0b0-4087-d12a-e718-c18ccb6811e6
10 mg 2 times / day steady, intravenous Dose: 10 mg, 2 times / day Route: intravenous Route: steady Dose: 10 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01211522	unhealthy n = 192 Health Status: unhealthy Condition: Delirium Population Size: 192 Sources: https://clinicaltrials.gov/ct2/show/NCT01211522	Other AEs: Torsades de pointes, Electrocardiogram QTc interval prolonged... Other AEs: Torsades de pointes (serious, 2 patients) Electrocardiogram QTc interval prolonged (below serious, 13 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01211522
10 mg 2 times / day steady, oral Dose: 10 mg, 2 times / day Route: oral Route: steady Dose: 10 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00129220	unhealthy n = 20 Health Status: unhealthy Condition: Bipolar I Disorder Population Size: 20 Sources: https://clinicaltrials.gov/ct2/show/NCT00129220	Other AEs: Cheilitis, Constipation... Other AEs: Cheilitis (below serious, 1 patient) Constipation (below serious, 2 patients) Salivary hypersecretion (below serious, 1 patient) Vomiting (below serious, 1 patient) Malaise (below serious, 2 patients) Thirst (below serious, 1 patient) Fall (below serious, 1 patient) Blood pressure decreased (below serious, 1 patient) Weight increased (below serious, 1 patient) Increased appetite (below serious, 1 patient) Arthralgia (below serious, 1 patient) Osteoarthritis (below serious, 1 patient) Akathisia (below serious, 3 patients) Dystonia (below serious, 3 patients) Headache (below serious, 1 patient) Sedation (below serious, 1 patient) Tremor (below serious, 2 patients) Depressive symptom (below serious, 1 patient) Insomnia (below serious, 1 patient) Mania (below serious, 1 patient) Pruritus (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT00129220

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 882 inhibitor 753	substrate 530 inhibitor 825	substrate 610 activator 7 inhibitor 894	inhibitor 775

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2J2 7 P-gp 666 OCT1 254 BCRP 303 MRP2 184 MDR3 4 Kv4.3 8 CYP1A2 725 CYP2A6 334 CYP2C8 417 CYP2C19 700 CYP2E1 424 BSEP 185 MRP3 80 MRP4 107 OATP1B1 369 OATP1B3 319	CYP1A2 526 CYP1A1 179 CYP2C8 354 CYP2C19 500 CYP3A5 203 UGT 90 UGT1A1 198 UGT1A3 195 UGT1A4 171 UGT1A6 148 UGT1A9 180 UGT2B7 182 UGT2B15 96 P-gp 724 OCT1 158 MATE1 64

Drug as perpetrator

Target	Modality	Activity
CYP2D6 908	inhibitor 1612 Sources: https://link.springer.com/article/10.1007/s40262-016-0407-2/tables/3 \| https://pubmed.ncbi.nlm.nih.gov/10460810/	moderate [Ki 7.2 uM]
CYP2A6 356	inhibitor 1612 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDU0In19	no [IC50 >10 uM]
CYP2E1 467	inhibitor 1612 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDU0In19	no [IC50 >10 uM]
MRP2 239	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/19421845/, https://pubmed.ncbi.nlm.nih.gov/23956101/, https://pubmed.ncbi.nlm.nih.gov/18457386/	no [IC50 >133 uM]
MRP3 113	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP4 124	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
CYP2C8 448	inhibitor 1612 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336800/	no [IC50 >30 uM]
CYP1A2 805	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/9431831/, https://pubmed.ncbi.nlm.nih.gov/23033255/	no [IC50 >50 uM]
BCRP 346	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/19421845/	no
CYP2C9 851	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/9431831/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDU0In19	yes [Activation 31.6228 uM]
MDR3 4	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/26335978/	yes [IC50 10.7 uM]
OCT1 266	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/18788725/	yes [IC50 141.9 uM]
CYP2C19 738	inhibitor 1612 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336800/	yes [IC50 2.87 uM]
BSEP 186	inhibitor 1612 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891329/, https://pubmed.ncbi.nlm.nih.gov/23956101/	yes [IC50 25.3 uM]
P-gp 754	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/16810505/	yes [IC50 25.4 uM]
Kv4.3 8	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/24998874/	yes [IC50 3.6 uM]
CYP2J2 8	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/23033255/	yes [IC50 4.69 uM]
CYP3A4 920	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/9431831/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336800/	yes [IC50 8.2 uM]
CYP2D6 908	activator 106 Sources: https://pubmed.ncbi.nlm.nih.gov/9681669/, https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000052868	yes
OATP1B1 379	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes
OATP1B3 326	inhibitor 1612 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
P-gp 724	substrate 1689 Sources: https://pubmed.ncbi.nlm.nih.gov/12031686/	likely [Km 33 uM]
UGT 90	substrate 1689 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf#page=8 Page: (Label) 8, 27	major
UGT2B7 182	substrate 1689 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	major
CYP2D6 610	substrate 1689 Sources: https://link.springer.com/article/10.1007/s40262-016-0407-2/tables/3, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf#page=9, https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.02d&code=C537&ns=ncit&type=relationship&key=113214754&b=1&n=0&vse=null Page: (Label) 9, 28	major	yes (co-administration study) Comment: Coadministration of CYP2D6 inhibitors (chlorpromazine, promethazine, quinidine, paroxetine, sertraline, venlafaxine) increased Haloperidol plasma concentrations. Sources: https://link.springer.com/article/10.1007/s40262-016-0407-2/tables/3, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf#page=9, https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.02d&code=C537&ns=ncit&type=relationship&key=113214754&b=1&n=0&vse=null Page: (Label) 9, 28
CYP3A4 882	substrate 1689 Sources: https://link.springer.com/article/10.1007/s40262-016-0407-2/tables/3, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf#page=9, https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.02d&code=C537&ns=ncit&type=relationship&key=113214754&b=1&n=0&vse=null Page: (Label) 9, 28	major	yes (co-administration study) Comment: Coadministration of Rifampicin (strong CYP3A4 inducer) decreased plasma Haloperidol levels by a mean of 70%. Sources: https://link.springer.com/article/10.1007/s40262-016-0407-2/tables/3, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf#page=9, https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.02d&code=C537&ns=ncit&type=relationship&key=113214754&b=1&n=0&vse=null Page: (Label) 9, 28
CYP1A2 526	substrate 1689 Sources: https://link.springer.com/article/10.1007/s40262-016-0407-2/tables/3, https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.02d&code=C537&ns=ncit&type=relationship&key=113214754&b=1&n=0&vse=null	minor
UGT1A4 171	substrate 1689 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	minor
UGT1A9 180	substrate 1689 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	minor
UGT1A1 198	substrate 1689 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	no
UGT1A3 195	substrate 1689 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	no
UGT1A6 148	substrate 1689 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	no
UGT2B15 96	substrate 1689 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	no
CYP1A1 179	substrate 1689 Sources: https://pubmed.ncbi.nlm.nih.gov/11717183/	yes
CYP2C19 500	substrate 1689 Sources: https://pubmed.ncbi.nlm.nih.gov/11717183/	yes
CYP2C8 354	substrate 1689 Sources: https://pubmed.ncbi.nlm.nih.gov/11717183/	yes
CYP2C9 530	substrate 1689 Sources: https://pubmed.ncbi.nlm.nih.gov/11717183/	yes
CYP3A5 203	substrate 1689 Sources: https://pubmed.ncbi.nlm.nih.gov/11717183/	yes
MATE1 64	substrate 1689 Sources: https://pubmed.ncbi.nlm.nih.gov/31842924/	yes
OCT1 158	substrate 1689 Sources: https://pubmed.ncbi.nlm.nih.gov/31842924/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 796	inhibitor 786 Sources: https://pubmed.ncbi.nlm.nih.gov/18448342/, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf#page=9, https://bpspubs.onlinelibrary.wiley.com/doi/epdf/10.1038/sj.bjp.0705025 Page: (Label) 9, 28

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:5613	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5613
ChemicalBook	CB32131152	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB32131152
ChemicalBook	CB72509133	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB72509133
ChemicalBook	CB7774829	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7774829
MolPort	MolPort-000-883-311	https://www.molport.com/shop/molecule-link/MolPort-000-883-311
Selleck Chemicals	Haloperidol(Haldol)	http://www.selleckchem.com/products/Haloperidol(Haldol).html
ZINC	ZINC000000537822	http://zinc15.docking.org/substances/ZINC000000537822
eMolecules	538987	https://www.emolecules.com/cgi-bin/more?vid=538987

PubMed

Title	Date	PubMed
Atypical tardive dyskinesia.	1975 May	1119614
Drug-induced dystonia.	1975 May	1119613
Catalepsy induced by morphine or haloperidol: effects of apomorphine and anticholinergic drugs.	1976 Aug	10058
The anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved?	1999	10651103
Locomotor activity and accumbens Fos expression driven by ventral hippocampal stimulation require D1 and D2 receptors.	1999	10613497
Modulatory effects of PLG and its peptidomimetics on haloperidol-induced catalepsy in rats.	1999	10477133
Neurotransmitter-mediated open-field behavioral action of CGRP.	1999	10075105
Synergistic interactions between ampakines and antipsychotic drugs.	1999 Apr	10087029
Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury.	1999 Dec	10628507
Haloperidol-induced within-session response decrement patterns and catalepsy in rats: behavioural dissociation.	1999 Feb	10780307
Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist.	1999 Feb	10188965
Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.	1999 Jul	10468314
Safety of amisulpride (Solian): a review of 11 clinical studies.	1999 Jul	10468313
New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects.	1999 Jun	10435384
Molecular and behavioral effects mediated by Gs-coupled adenosine A2a, but not serotonin 5-Ht4 or 5-Ht6 receptors following antipsychotic administration.	1999 Mar	10199625
Behavioral effects following single and combined maternal exposure to PCB 77 (3,4,3',4'-tetrachlorobiphenyl) and PCB 47 (2,4,2',4'-tetrachlorobiphenyl) in rats.	1999 Mar-Apr	10192275
Effects of SCH 23390, raclopride, and haloperidol on morphine withdrawal-induced aggression in male mice.	1999 Sep	10495006
Identification of quantitative trait loci for haloperidol-induced catalepsy on mouse chromosome 14.	1999 Sep	10454512
Inhibition by various antipsychotic drugs of the G-protein-activated inwardly rectifying K(+) (GIRK) channels expressed in xenopus oocytes.	2000 Apr	10780978
Estrogen priming modulates autoreceptor-mediated potentiation of dopamine uptake.	2000 Aug 11	10936494
Effect of genetic cross on the detection of quantitative trait loci and a novel approach to mapping QTLs.	2000 Dec	11166067
Prolonged upper airway instability in the parenteral use of benzodiazepine with levomepromazine.	2000 Feb	10653217
Prolactin regulation of tuberoinfundibular dopaminergic neurons: immunoneutralization studies.	2000 Jan 3	10661492
Manic episode in an ifosfamide-treated patient.	2000 Jan-Feb	10766557
Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy.	2000 Jun	11103884
Effect of dopamine agonists and antagonists on the lorazepam withdrawal syndrome in rats.	2000 Mar	10744342
Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice.	2000 May	10888308
Biperiden hydrochlorate ameliorates dystonia of rats produced by microinjection of sigma ligands into the red nucleus.	2000 Nov	11164078
Enhancement of haloperidol-induced catalepsy by nicotine: an investigation of possible mechanisms.	2000 Nov	11100936
Contrasting patterns and cellular specificity of transcriptional regulation of the nuclear receptor nerve growth factor-inducible B by haloperidol and clozapine in the rat forebrain.	2000 Oct	10987852
Haloperidol-induced impotence improved by switching to olanzapine.	2000 Sep-Oct	11203037
FosB in rat striatum: normal regional distribution and enhanced expression after 6-month haloperidol administration.	2001 Feb	11180499
The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice.	2001 Feb 13	11172060
Double activity imaging reveals distinct cellular targets of haloperidol, clozapine and dopamine D(3) receptor selective RGH-1756.	2001 Mar	11166331

Patents

Sample Use Guides

In Vivo Use Guide

Parenteral medication, administered intramuscularly in doses of 2 to 5 mg, is utilized for prompt control of the acutely agitated schizophrenic patient with moderately severe to very severe symptoms. Depending on the response of the patient, subsequent doses may be given, administered as often as every hour, although 4 to 8 hour intervals may be satisfactory.

Route of Administration: Intramuscular

In Vitro Use Guide

10 uM Haloperidol induced a 54% decrease in the mRNA expression of ABCA1 in murineperitoneal macrophages.

Name

Type

Language

HALOPERIDOL

Official Name

English

HALOPERIDOL DECANOATE SPECIFIED IMPURITY G [EP]

Common Name

English

HALOPERIDOL COMPONENT OF VESALIUM

Brand Name

English

EUKYSTOL

Common Name

English

VESALIUM COMPONENT HALOPERIDOL

Brand Name

English

HALOPERIDOL [HSDB]

Common Name

English

HALOPERIDOL [WHO-IP]

Common Name

English

SIGAPERIDOL

Common Name

English

HALDOL

Brand Name

English

KESELAN

Common Name

English

ALOPERIDIN

Common Name

English

HALOPERIDOL [WHO-DD]

Common Name

English

NSC-170973

Code

English

HALOPERIDOL [EP MONOGRAPH]

Common Name

English

R-1625

Code

English

NSC-615296

Code

English

HALOPERIDOLUM [WHO-IP LATIN]

Common Name

English

SERENELFI

Common Name

English

SERENASE

Common Name

English

BIOPERIDOLO

Common Name

English

1-BUTANONE, 4-(4-(4-CHLOROPHENYL)-4-HYDROXY-1-PIPERIDINYL)-1-(4-FLUOROPHENYL)-

Systematic Name

English

HALOPERIDOL [USP]

Common Name

English

HALOPERIDOL [MI]

Common Name

English

SERENACE

Common Name

English

HALOPERIDOL [USP MONOGRAPH]

Common Name

English

HALOPERIDOL DECANOATE IMPURITY, HALOPERIDOL- [USP]

Common Name

English

HALOPERIDOL [MART.]

Common Name

English

NEURODOL

Common Name

English

LINTON

Common Name

English

HALOPERIDOL [ORANGE BOOK]

Common Name

English

HALOPERIDOL [USAN]

Common Name

English

HALOPERIDOL [INN]

Common Name

English

HALOPERIDOL [VANDF]

Common Name

English

DOZIC

Common Name

English

HALOPERIDOL [USP-RS]

Common Name

English

Classification Tree Code System Code

LIVERTOX

476